FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to pharmaceutical industry, namely to a method of determining thrombocyte sensitivity. Method for determining sensitivity of thrombocytes to acetylsalicylic acid (ASA), involving blood sampling, wherein analyzing ADP-induced lucigenin-dependent chemoluminescence of thrombocytes; by area (S) value under a chemiluminescence curve resistance of thrombocytes to ASA is determined: S<360,000 standard units indicates thrombocyte resistance to ASA, if S≥360,000, then thrombocyte sensitivity to ASA is stated.
EFFECT: disclosed invention enables effective diagnosis of ASA resistance in a patient.
1 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR RAPID DIAGNOSIS OF RESISTANCE AND SUSCEPTIBILITY TO ACETYLSALICYLIC ACID | 2015 |
|
RU2578428C1 |
| METHOD OF DIAGNOSING RESISTANCE TO ACETYLSALICYLIC ACID | 2009 |
|
RU2413953C1 |
| METHOD OF DETERMINING ANTI-THROMBOTIC EFFECT OF ACETYLSALICYLIC ACID | 2007 |
|
RU2379684C2 |
| METHOD FOR PREDICTION OF ANTIPLATELET THERAPY EFFICIENCY REDUCTION RISK | 2016 |
|
RU2623051C1 |
| METHOD OF DETERMINING PLATELET RESISTANCE TO ACETYLSALICYLIC ACID | 2013 |
|
RU2538219C2 |
| METHOD OF INDIVIDUAL PROGNOSIS OF CLINICAL EFFECTIVENESS OF DUAL ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME | 2016 |
|
RU2639772C1 |
| METHOD FOR PREVENTION OF THROMBOSIS IN INDIVIDUALS SUFFERING CARDIOVASCULAR DISEASES AND CHRONIC PAIN | 2013 |
|
RU2528904C1 |
| METHOD OF DETERMINING THROMBOCYTE RESISTANCE TO DOUBLE ANTIPLATELET THERAPY IN PATIENTS WITH ISCHEMIC HEART DISEASE | 2019 |
|
RU2710272C1 |
| METHOD FOR DIAGNOSTICS OF ASPIRIN RESISTANCE IN PATIENTS WITH CORONARY HEART DISEASE | 2007 |
|
RU2348041C1 |
| COMBINED ANTIAGGREGANT AND ANTIOXIDANT | 2010 |
|
RU2430728C1 |
